Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion
{{output}}
Ublituximab, a newly launched anti-CD20 monoclonal antibody, represents a substantial advancement in the treatment landscape for relapsing multiple sclerosis (RMS). Its unique glycoengineered design enhances antibody-dependent cellular cytotoxicity, enabling r... ...
